RxDoctor Payments Data

Conrado de Leon, MD

Pediatrics · Moses Lake, WANPI 1427060987

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 69 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boehringer Ingelheim accounts for 62.0% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $328 and has fallen 62.9% since, to $122 in 2024. Among pediatrics clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,493in general payments, 2019–2025

Across 69 payments — averaging $21.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$927
  • Amarin Pharma, Inc.$202
  • AstraZeneca$154
  • Lilly USA, LLC$118
  • Novo Nordisk$42
  • Abbott$27
  • plus $23 from 1 others

What the payments were for

  • Food & beverage$1,493100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,493 in reported general payments places this provider in the 95th percentile of 721 pediatrics providers in Washington.

See all pediatrics providers in Washington

Medicare billing

Part B allowed, 2024
$30,753
Medicare patients
35
Services billed
257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide14$12,929
AdderallDextroamphetamine/Amphetamine12$11,245
JardianceEmpagliflozin12$10,529
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen132$2,730
Oxycodone Hcl64$2,425
Gabapentin32$641
Morphine Sulfate ErMorphine Sulfate22$435
Levothyroxine Sodium49$427
Amlodipine Besylate49$340
Lorazepam21$328
Atorvastatin Calcium48$305
Tramadol Hcl50$298
Lisinopril55$263
Zolpidem Tartrate35$211
Duloxetine Hcl14$180

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$118$12,92914 claims
Boehringer IngelheimJardiance$927$10,52912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 721 pediatrics providers in Washington.

Other pediatrics in Moses Lake

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →